News | May 14, 2025
GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Strong topline growth driven by solid performance across key brands.
This tie-up will have no impact on any other brands of the company
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Subscribe To Our Newsletter & Stay Updated
